Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 13

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---
”). Moreover, in the event that an executed waiver is deemed to be
unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims.
The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors
by endeavoring to have all vendors, service providers (except for the Company’s independent registered public accounting firm),
prospective target businesses and other entities with which the Company does business, execute agreements with the Company waiving any
right, title, interest or claim of any kind in or to monies held in the Trust Account.

Going
Concern Consideration

As
of September 30, 2025, the Company had $717 in cash and a working capital deficit of $428,415. The Company has incurred and expects to
continue to incur significant costs in pursuit of its financing and acquisition plans. Additionally, the date for mandatory liquidation
and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. These conditions
raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited
financial statements are issued. Management plans to address this uncertainty through a Business Combination. There is no assurance that
the Company’s plans to raise capital or to consummate a Business Combination will be successful within the Combination Period.
The financial statement does not include any adjustments that might result from the outcome of this uncertainty.

7

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

NOTE
2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis
of Presentation

The
accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article
8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance
with GAAP have been omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not
include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash
flows. In the opinion of management, the accompanying unaudited financial statements include all adjustments